FIELD: medicine; pharmaceutics.
SUBSTANCE: object 1 is a pharmaceutical composition for preventing or treating a malignant tumour, containing as active ingredients a dimeric fusion protein, containing a variant of IL-2, containing amino acid substitutions R38A and F42A in SEQ ID NO: 10, and an extracellular domain of the CD80 protein, and an immune control point inhibitor, which is selected from a group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody and an anti-TIGIT antibody. Object 2 is a method of preventing or treating a malignant tumour, comprising administering to an individual having a malignant tumour, a dimeric fusion protein comprising a variant of IL-2, containing amino acid substitutions R38A and F42A in SEQ ID NO: 10, and an extracellular domain of the CD80 protein, and an immune control point inhibitor, which is selected from a group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody and an anti-TIGIT antibody.
EFFECT: synergetic effect of dimeric fusion protein introduction in combination with immune control point inhibitor.
6 cl, 76 dwg, 8 tbl, 33 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN AND ITS USE | 2019 |
|
RU2811541C2 |
| PROTEINS WITH A DOUBLE FUNCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2016 |
|
RU2741345C2 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN | 2018 |
|
RU2813996C2 |
| FGF21 FUSED WITH LONG-ACTING PROTEINS AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2016 |
|
RU2741087C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| NEW MODIFIED IMMUNOGLOBULIN Fc-FRAGMENT FUNCTION PROTEIN AND ITS USE | 2020 |
|
RU2800919C2 |
